Greenwich LifeSciences (NASDAQ: GLSI) completed an at‑the‑market equity offering that raised enough capital to exceed its quarterly cash burn rate, leaving the company with a cash balance of approximately $10.5 million as of March 31 2026. The proceeds were not disclosed, but the fact that they surpassed the burn rate represents a significant liquidity event for a pre‑revenue biopharma that has historically operated on a three‑month runway.
The new cash balance is a dramatic increase from the $3.8 million reported on September 30 2025 and the $2.75 million on March 31 2025. With an annual burn of roughly $9.5 million in 2025 and $7 million in 2024 and 2023, the ATM proceeds extend the company’s runway by at least one additional quarter, providing a temporary buffer as it continues to fund the Flamingo‑01 Phase III trial and associated site activation costs.
The company’s primary use of the capital is to support the Flamingo‑01 Phase III study, the pivotal trial for its investigational immunotherapy GLSI‑100. The trial’s progress, combined with the company’s Fast Track designation, underpins the strategic importance of the funding, allowing the company to maintain momentum without immediately resorting to a more dilutive capital raise.
Greenwich LifeSciences remains a pre‑revenue entity with net losses of $3.26 million in Q1 2025 and $4.15 million in Q3 2025. The company has historically relied on ATM offerings for financing, including a $7 million raise in early January 2026. The current cash position, while improved, still reflects a precarious financial position as the company pursues regulatory approval for GLSI‑100.
The ATM offering, coupled with the company’s Fast Track status and ongoing trial progress, positions Greenwich LifeSciences to navigate the next phase of development. However, the need for continued financing remains, and the company’s limited revenue stream underscores the importance of maintaining liquidity to reach regulatory milestones.
In summary, the ATM offering has extended Greenwich LifeSciences’ cash runway, bolstered its ability to fund a critical Phase III trial, and reinforced its strategic trajectory, while highlighting the ongoing financial challenges typical of a pre‑revenue biopharmaceutical company.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.